Therefore, this therapeutic strategy could improve the management of patients with T2DM and DKD with obesity or preserved insulin reserve, as it can be safely administered in those patients with impaired kidney function (eGFR > 15 mL/min/1.73 m2). The gene discussed is INS; the disease is obesity disorder.